Last reviewed · How we verify
Placebo (for Selenium)
A placebo has no active pharmacological mechanism; it serves as a control comparator in clinical trials.
A placebo has no active pharmacological mechanism; it serves as a control comparator in clinical trials. Used for Control arm in Phase 3 trial for selenium supplementation (indication under investigation).
At a glance
| Generic name | Placebo (for Selenium) |
|---|---|
| Also known as | control |
| Sponsor | Oswaldo Cruz Foundation |
| Modality | Small molecule |
| Therapeutic area | Nutritional/Micronutrient supplementation |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used in randomized controlled trials to establish the true efficacy of an investigational drug by comparison to a non-active control. Any observed effects in the placebo arm are attributed to natural disease progression, regression to the mean, or the placebo effect itself. In this case, the placebo is being used as a control in a Phase 3 trial evaluating selenium supplementation.
Approved indications
- Control arm in Phase 3 trial for selenium supplementation (indication under investigation)
Common side effects
Key clinical trials
- Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies (PHASE2)
- Alii Supplement Study (PHASE2)
- Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy (NA)
- Selenium Supplementation for Improving Depression in Children and Adolescents: Efficacy and Mechanistic Study (PHASE2)
- The SELEQT-HF (SELEnium and CoQ10 NuTrition for Heart Failure) Study Will Evaluate the Effect of Adding Selenium/and coQ10 on Top of Standard HF Therapy in Patients With HF and Will do so Using a Pragmatic, Registry Based Randomized Controlled Trial in the Netherlands. (PHASE3)
- This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control (PHASE4)
- Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. (PHASE4)
- Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Selenium) CI brief — competitive landscape report
- Placebo (for Selenium) updates RSS · CI watch RSS
- Oswaldo Cruz Foundation portfolio CI